|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Ann Thorac Surg 1995;60:902
© 1995 The Society of Thoracic Surgeons
| The first 20% of the full text of this article appears below. |
See also page 896.
DR DAVID J. SUGARBAKER (Boston, MA): It is interesting that you can relate the survival of patients presenting with superficial carcinoma to that of those who have been downstaged presumably from some greater stage in this particular study. Can you tell us how you determined that those patients before induction therapy were at some greater stage with or without nodal metastases, T3 invasion?
DR DOUGLAS J. MATHISEN (Boston, MA): I am curious what your surveillance program is that leads to the increased number of patients. It is an issue that all of us struggle with, and I am just curious what type of surveillance program is used at the Cleveland Clinic.
How do you identify the patients with very early lesions and decide not to pretreat them with chemotherapy or some sort of adjuvant program beforehand? Do you use ultrasound, or is it a visual identification alone? How do you decide which patients you are going to pretreat? If you think there is a very early lesion, Tis or T1, do you elect not to treat with preoperative chemotherapy and just operate?
DR F. GRIFFITH PEARSON (Toronto, Ontario): Of interest in this paper to me when I went through the abstract is the rather disappointing survival
Related Article
Ann. Thorac. Surg. 1995 60: 896-901.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |